A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases

Trial Profile

A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 18 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 18 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top